'Pivotal' trial results display favorable outcomes for use of TPV device

May 15, 2020

WASHINGTON - A percutaneous transcatheter therapy for congenital heart disease (CHD) patients with severe pulmonary regurgitation (PR) has been slow to materialize, in comparison to transcatheter pulmonary valve (TPV) therapy for a dysfunctional surgical RV-PA conduit which was first implanted twenty years ago as the Melody TPV. Findings from the Medtronic Harmony TPV Pivotal Trial were presented today during the SCAI 2020 Scientific Sessions Virtual Conference and showed favorable outcomes utilizing the device in patients with severe PR.

Pulmonary regurgitation occurs when a patient has a leaky pulmonary valve, which allows flow back into the right ventricle heart chamber before it gets to the lungs for oxygen. This usually occurs after failure over time of a surgical correction of obstruction of the right ventricular outflow tract (RVOT).

The Harmony TPV is a self-expandable covered frame with a porcine pericardial valve inside that accommodates the larger right ventricular outflow tract (RVOT) of patients with congenital defects who develop severe PR after surgical repair. The TPV is available in 22- and 25-mm sizes with differences in frame size and length. An Early Feasibility Study (EFS) with TPV 22 showed high procedural success, safety, and favorable device performance through three years.

The Pivotal Trial is ongoing at 12 sites in the United States, Canada, and Japan. Patients with severe PR on echocardiography or PR fraction ?30% by magnetic resonance imaging and an indication for surgical placement of a RV-pulmonary artery conduit or prosthetic PV were eligible. Forty patients were implanted and ten patients subsequently received a modified version of the TPV 25. The primary safety endpoint is freedom from procedure- or device-related mortality at 30 days. The primary effectiveness endpoint is acceptable hemodynamic function at six months, defined as mean RVOT gradient ?40 mmHg on echocardiography, PR fraction <20% on magnetic resonance imaging; and no prior TPV reintervention. For the modified TPV 25, 30-day hemodynamic performance and safety is reported.

The investigators reported that the median age of patients in the study was 28 years old with 92% having a diagnosis of. Tetralogy of Fallot. The primary indication for intervention was severe PR in 94%, while 6% had moderate PR. The femoral vein was used in 94% of the patients to deliver the Harmony TPV. Freedom from procedure- or device- related mortality at 30 days was 100%. The measured efficacy for the Pivotal Trial (a composite of acceptable hemodynamics and no catheter interventions) was 89% and increased to 91% when including the EFS patients (versus a performance target of 75%, meeting the primary efficacy endpoint). Freedom from TPV dysfunction was 89% at 6 months. At six months, the mean RVOT gradient remained low at 14.6mmHg, while residual significant PR was only 6% with only 3% having moderate paravalvular leak (PVL). The Harmony TPV Pivotal Trial met its intended safety and efficacy goals

"Until recently, the only option for a patient that had severe PR after previous open heart surgery was to return to the operating room for another open heart surgical procedure, either a bioprosthetic Pulmonary Valve replacement or an RV-PA conduit," said John P. Cheatham, MD, Interventional Cardiologist in The Heart Center at Nationwide Children's Hospital , and Professor Emeritus at The Ohio State University in Columbus, OH. Dr. Cheatham also serves as the lead Principal Investigator of the Harmony Trials. "The Harmony TPV therapy finally offered a non-surgical option to treat severe PR and restore pulmonary valve competence."

Abstract #10994 "Primary Outcomes of the Harmony Transcatheter Pulmonary Valve Pivotal Trial." SCAI 2020 Scientific Sessions Virtual Conference, May 14-16, 2020.
-end-
About the Society for Cardiovascular Angiography and Interventions

The Society for Cardiovascular Angiography and Interventions (SCAI) is a professional member organization representing 5,000 invasive and interventional cardiologists in approximately 75 nations. SCAI's mission is to promote excellence invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. For more information about SCAI, visit http://www.scai.org and http://www.secondscount.org. Follow @SCAI on Twitter for the latest heart health news.

Society for Cardiovascular Angiography and Interventions

Related Congenital Heart Disease Articles from Brightsurf:

Low risk of COVID-19 infection found among people with congenital heart disease
Results of a retrospective analysis suggest that people born with a heart defect who developed COVID-19 symptoms had a low risk of moderate or severe COVID-19 infection, according to a new article published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.

New method for in utero 4D imaging of baby hearts may aid diagnosis of congenital heart disease
Researchers at King's College London have developed a new method for helping detect congenital heart disease of a baby in pregnant mothers using MRI.

Gout treatment may aid patients with congenital heart disease
A drug used to treat gout, probenecid, may improve heart function in individuals with a particular heart defect, according to results from a small pilot study run by a University of Cincinnati researcher.

Stakeholders update newborn screening guidelines for critical congenital heart disease
A distinguished panel of medical experts, state and federal health officials, and congenital heart disease parent advocates published recommended updates to the current American Academy of Pediatrics' protocol for detecting critical congenital heart disease (CCHD) in newborn babies using pulse oximetry.

Congenital heart disease more deadly in low-income countries
Even though mortality from congenital heart disease (CHD) has declined over the last three decades as diagnosis and treatments have advanced, a new study shows that the chances for a child to survive a CHD diagnosis significantly differs based on the country where he or she is born.

Telehealth effectively diagnoses/manages fetal congenital heart disease in rural patients
A recent study of 368 pregnant mothers, led by Bettina Cuneo, MD, director of perinatal cardiology and fetal cardiac telemedicine at Children's Hospital Colorado, found that fetal congenital heart disease (CHD) was correctly identified and successfully managed according to evidence-based risk stratification.

Uncorrected congenital heart disease may lead to increased risks in pregnant women
Pregnant women with congenital heart disease (CHD) who have not had surgery to repair their cardiac condition are more likely to experience cardiac events or maternal death, especially those with certain conditions in emerging countries, according to a study published Oct.

A new framework to study congenital heart defects
In a new study published in the scientific journal Nature, a team of researchers at the Gladstone Institutes, in collaboration with the University of Luxembourg, reveal for the first time the full spectrum of cells that come together to make a heart at the earliest stages of embryo formation.

Risk of cancer among children, young adults with congenital heart disease
National registry data in Sweden were used in this study that assessed the risk of developing cancer in children and young adults with congenital heart disease compared with healthy people in the general population from birth to age 41.

Congenital heart defects vastly increase risk of heart problems later in life
An infant born with a relatively simple heart defect is far more likely to develop heart problems as an adult, researchers at the Stanford University School of Medicine have discovered.

Read More: Congenital Heart Disease News and Congenital Heart Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.